Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the thirteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.73.
FATE has been the subject of several research analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday. Wedbush reiterated a “neutral” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Monday, May 6th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Wednesday, August 14th. StockNews.com cut shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 10th. Finally, BMO Capital Markets decreased their price target on Fate Therapeutics from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th.
View Our Latest Report on Fate Therapeutics
Institutional Trading of Fate Therapeutics
Fate Therapeutics Stock Up 1.9 %
Shares of Fate Therapeutics stock opened at $3.84 on Friday. The firm has a market cap of $437.11 million, a price-to-earnings ratio of -2.00 and a beta of 1.90. Fate Therapeutics has a 52-week low of $1.63 and a 52-week high of $8.83. The company’s 50-day simple moving average is $3.91 and its 200-day simple moving average is $5.00.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.14. The company had revenue of $6.77 million for the quarter, compared to analyst estimates of $1.47 million. Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%. Equities research analysts anticipate that Fate Therapeutics will post -1.9 EPS for the current year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Recommended Stories
- Five stocks we like better than Fate Therapeutics
- 10 Best Airline Stocks to Buy
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 8/19 – 8/23
- Upcoming IPO Stock Lockup Period, Explained
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.